Tissue Transplant and Regeneration Device and Method to Treat Ischemic Heart Disease (BIDMC 960)

Category:    Medical Devices

KeyWords:  Surgery;  

BIDMC ID:    960

Abstract:

Background: Myocardial infarction (MI) remains the leading cause of mortality and morbidity in the Western world despite advancements in the treatment of coronary artery disease. Once the MI scar develops, the ventricle undergoes unfavorable remodeling resulting in left ventricular dilation and decreased ejection fraction. Post-infarction heart failure (HF) has 50% mortality in 5 years from symptom onset. With advanced HF refractory to medical management, heart transplantation is the only option for younger individuals. The shortage of organs, however, warrants alternative treatment strategies to enhance myocardial regeneration and repair. Invention: A novel minimally-invasive method and device are described for the implantation of autologous adult myotissue to treat the myocardial infarct scar. Biopsies of myocardial tissue are obtained from the preserved ventricular septum and used for implantation into the myocardial scar tissue with their intact milieu and without the need for ex vivo culturing or manipulation. The safety and efficacy of the method in limiting left ventricular dysfunction post MI have been demonstrated in a porcine model of myocardial infarction.

Inventor:   Roger Laham, MD

Commercial Opportunity:

Competitive Advantages:

The procedure is simple, safe and effective. Unlike similar cell-based therapies, the present procedure obviates the need for cell culture or manipulation of tissue prior to implantation

Related Publications:

“Autologous myotissue tranplantation in a porcine myocardial infarction model results in improved function and decreased infarct size” American College of Cardiology. 2005. Oral Presentation.

“Myotissue implants into myocardial infarct zone decreases infarct size and improves left ventricular function in infarct scar with increased cardiac stem cells” American Heart Assoc. 2005. Abstract.

“Myotissue transplantation for angiogenesis and myocardial regeneration”. 2006. Transcatheter Cardiovascular Therapeutics Meeting.

State of Development:

Safety and feasibility have been demonstrated in a porcine model of MI.

Related Technology URL:

http://bidmc.harvard.edu/display.asp?leaf_id=7271

Patent Status:

US utility patent pending.

TVO Contact Info:
     Catherine M Lenich
     Senior Associate TVO
     clenich@bidmc.harvard.edu
     Phone: 617-667-0568   Fax: 617-667-0646

     Beth Israel Deaconess Medical Center
     Technology Ventures Office  Room: BR-0200
     330 Brookline Avenue
     Boston, MA 02215